Skip Navigation

European Heart Journal 2001 22(16):1504-1510; doi:10.1053/euhj.2000.2546
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (39)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Plewan, A
Right arrow Articles by Schmitt, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Plewan, A
Right arrow Articles by Schmitt, C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation. Sotalol vs bisoprolol

A Plewanf1, G Lehmann, G Ndrepepa, J Schreieck, E.U Alt, A Schömig and C Schmitt

German Heart Center and 1, Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

revised November 13, 2000; accepted November 22, 2000

Abstract

Aims The purpose of the study was to compare the efficacy and safety of sotalol and bisoprolol in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation.

Methods Patients (n=128) were randomized to sotalol (80mg b.i.d.) or bisoprolol (5mg.day–1). Patients with contraindications to beta-blockers, class III antiarrhythmic drugs or prior treatment with use of study medication for prevention of atrial fibrillation were excluded. Follow-up clinical evaluation was performed 1 day and 1 month after cardioversion and thereafter at 3-month intervals.

Results There were no group differences in baseline clinical characteristics. After a follow-up of 12 months, 59% of all patients were still in sinus rhythm. The fraction remaining in sinus rhythm was calculated for the two groups by Kaplan–Meier analysis. During follow-up, 41% of patients on sotalol and 42% on bisoprolol developed atrial fibrillation (ns). In two patients (3·1%) on sotalol, life-threatening proarrhythmias (torsade de pointes tachycardias) occurred, whereas none were found in the bisoprolol group. Symptomatic bradycardias occurred in two patients on sotalol and three on bisoprolol.

Conclusion This study demonstrates that sotalol (160mg.day–1) and bisoprolol (5mg.day–1) are equally effective in maintaining sinus rhythm. Because of the side effects of sotalol, bisoprolol seems to be advantageous for maintenance of sinus rhythm after cardioversion of atrial fibrillation.

Key Words: Atrial fibrillation, cardioversion, sotalol, bisoprolol

f1 Correspondence: Dr Andreas Plewan, 1. Medizinische Klinik Klinikum rechts der Isar, Ismaninger Strasse 22, D-81675 München, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EuropaceHome page
M. L. Hansen, N. Gadsboll, G. H. Gislason, S. Z. Abildstrom, T. K. Schramm, F. Folke, J. Friberg, R. Sorensen, S. Rasmussen, H. E. Poulsen, et al.
Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers
Europace, April 1, 2008; 10(4): 395 - 402.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
H.-R. Neuberger, C. Mewis, D. J. van Veldhuisen, U. Schotten, I. C. van Gelder, M. A. Allessie, and M. Bohm
Management of atrial fibrillation in patients with heart failure
Eur. Heart J., November 1, 2007; 28(21): 2568 - 2577.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. K Nergardh, M. Rosenqvist, R. Nordlander, and M. Frick
Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study
Eur. Heart J., June 1, 2007; 28(11): 1351 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 651 - 745.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246.
[Full Text] [PDF]

Home page
 CirculationHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation, August 15, 2006; 114(7): e257 - e354.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
C. Lafuente-Lafuente, S. Mouly, M. A. Longas-Tejero, I. Mahe, and J.-F. Bergmann
Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.
Arch Intern Med, April 10, 2006; 166(7): 719 - 728.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Shelton
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial
Eur. Heart J., December 1, 2004; 25(23): 2174 - 2174.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
T. Fetsch and G. Breithardt
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial
Eur. Heart J., December 1, 2004; 25(23): 2174 - 2175.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al.
Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology
Eur. Heart J., August 1, 2004; 25(15): 1341 - 1362.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. J Workman, K. A Kane, J. A Russell, J. Norrie, and A. C Rankin
Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling
Cardiovasc Res, June 1, 2003; 58(3): 518 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
H. Burri
Maintainance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation
Eur. Heart J., April 1, 2002; 23(7): 586 - 586.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Plewan
A reply
Eur. Heart J., April 1, 2002; 23(7): 586 - 586.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Coumel
Sotalol: a fool's deal?
Eur. Heart J., August 2, 2001; 22(16): 1370 - 1373.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.